BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
336.89
+2.49 (+0.74%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close334.40
Open333.46
Bid0.00 x 1100
Ask0.00 x 900
Day's Range332.49 - 338.46
52 Week Range249.17 - 388.67
Volume1,030,217
Avg. Volume1,616,796
Market Cap67.864B
Beta1.49
PE Ratio (TTM)23.92
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire15 days ago

    Biogen Enrolls First Patient in Global Phase 3 Study of BIIB093 (IV Glibenclamide) for Large Hemispheric Infarction

    CHARM study will evaluate IV glibenclamide for the prevention and treatment of severe cerebral edema in LHI, one of the most severe types of ischemic stroke with limited treatment options Prior studies ...

  • GlobeNewswire22 days ago

    Biogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab

    CAMBRIDGE, Mass., Aug. 28, 2018-- Biogen and Eisai Co., Ltd. announced results from a recent analysis of the ongoing long-term extension Phase 1 b study of aducanumab, an investigational treatment for ...

  • ACCESSWIRE2 months ago

    Free Stock Performance Review on Biogen and Three Additional Biotech Stocks

    This morning, WallStEquities.com observes BioDelivery Sciences International Inc. (NASDAQ: BDSI), Biohaven Pharmaceutical Holding Co. Ltd (NYSE: BHVN), Biogen Inc. (NASDAQ: BIIB), and Cerus Corp. (NASDAQ: CERS). The Biotechnology industry consists of companies that are engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development.

  • GlobeNewswire2 months ago

    New Research Coverage Highlights Texas Instruments, Biogen, Sanchez Energy, Amazon, Sirius XM, and JPMorgan Chase — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, July 30, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Texas ...

  • GlobeNewswire2 months ago

    Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer's Disease at Alzheimer's Association International Conference (AAIC) 2018

    TOKYO and CAMBRIDGE, Mass., July  25, 2018  (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced detailed results from the Phase II study (Study 201) with BAN2401, an anti-amyloid beta (ABeta) protofibril antibody, in 856 patients with early Alzheimer`s disease as part of Session DT-01 "Recent Developments in Therapeutics" (Presentation number: DT-01-07) at the Alzheimer`s Association International Conference (AAIC) 2018 being held in Chicago, Illinois, United States on July 25. Study 201 (ClinicalTrials.gov identifier NCT01767311) is a placebo-controlled, double-blind, parallel-group, randomized Phase II clinical study in 856 patients with mild cognitive impairment (MCI) due to Alzheimer`s disease or mild Alzheimer`s dementia (collectively known as early Alzheimer`s disease) with confirmed amyloid pathology in the brain.

  • GlobeNewswire2 months ago

    Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018

    Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”) announced detailed results from the Phase II study (Study 201) with BAN2401, an anti-amyloid beta (Aβ) protofibril antibody, in 856 patients with early Alzheimer's disease as part of Session DT-01 “Recent Developments in Therapeutics” (Presentation number: DT-01-07) at the Alzheimer’s Association International Conference (AAIC) 2018 being held in Chicago, Illinois, United States on July 25. Study 201 (ClinicalTrials.gov identifier NCT01767311) is a placebo-controlled, double-blind, parallel-group, randomized Phase II clinical study in 856 patients with mild cognitive impairment (MCI) due to Alzheimer's disease or mild Alzheimer's dementia (collectively known as early Alzheimer’s disease) with confirmed amyloid pathology in the brain.

  • PR Newswire2 months ago

    Eisai And Biogen Announce Detailed Results Of Phase II Clinical Study Of BAN2401 In Early Alzheimer's Disease At Alzheimer's Association International Conference (AAIC) 2018

    TOKYO and CAMBRIDGE, Mass., July 25, 2018 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced detailed results from the Phase II study (Study 201) with BAN2401, an anti-amyloid beta (Aβ) protofibril antibody, in 856 patients with early Alzheimer's disease as part of Session DT-01 "Recent Developments in Therapeutics" (Presentation number: DT-01-07) at the Alzheimer's Association International Conference (AAIC) 2018 being held in Chicago, Illinois, United States on July 25. Study 201 (ClinicalTrials.gov identifier NCT01767311) is a placebo-controlled, double-blind, parallel-group, randomized Phase II clinical study in 856 patients with mild cognitive impairment (MCI) due to Alzheimer's disease or mild Alzheimer's dementia (collectively known as early Alzheimer's disease) with confirmed amyloid pathology in the brain.

  • GlobeNewswire2 months ago

    Eisai and Biogen Present Detailed Results From Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer's Disease at Alzheimer's Association International Conference (AAIC) 2018

    Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced detailed results from a Phase II clinical study (Study 202) of the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) at the Alzheimer`s Association International Conference (AAIC) 2018 being held in Chicago, Illinois, United States, from July 22 to 26, 2018. Study 202 (ClinicalTrials.gov identifier NCT02322021) is a multicenter, randomized, double-blind, placebo-controlled parallel-group 18-month Phase II clinical study, conducted in the United States in patients with mild cognitive impairment (MCI) due to Alzheimer`s disease, or mild to moderate dementia due to Alzheimer`s disease (AD) with confirmed amyloid pathology by positron emission tomography (PET).

  • GlobeNewswire2 months ago

    Eisai and Biogen Present Detailed Results From Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018

    Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”) announced detailed results from a Phase II clinical study (Study 202) of the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) at the Alzheimer’s Association International Conference (AAIC) 2018 being held in Chicago, Illinois, United States, from July 22 to 26, 2018. Study 202 (ClinicalTrials.gov identifier NCT02322021) is a multicenter, randomized, double-blind, placebo-controlled parallel-group 18-month Phase II clinical study, conducted in the United States in patients with mild cognitive impairment (MCI) due to Alzheimer’s disease, or mild to moderate dementia due to Alzheimer’s disease (AD) with confirmed amyloid pathology by positron emission tomography (PET).

  • PR Newswire2 months ago

    Eisai And Biogen Present Detailed Results From Phase II Clinical Study Of Elenbecestat In MCI And Mild To Moderate Alzheimer's Disease At Alzheimer's Association International Conference (AAIC) 2018

    TOKYO and CAMBRIDGE, Mass., July 25, 2018 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced detailed results from a Phase II clinical study (Study 202) of the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) at the Alzheimer's Association International Conference (AAIC) 2018 being held in Chicago, Illinois, United States, from July 22 to 26, 2018. Study 202 (ClinicalTrials.gov identifier NCT02322021) is a multicenter, randomized, double-blind, placebo-controlled parallel-group 18-month Phase II clinical study, conducted in the United States in patients with mild cognitive impairment (MCI) due to Alzheimer's disease, or mild to moderate dementia due to Alzheimer's disease (AD) with confirmed amyloid pathology by positron emission tomography (PET).

  • ACCESSWIRE2 months ago

    These Biotech Stocks Should Be On Your Watch-List

    CORAL GABLES, FL / ACCESSWIRE / July 24, 2018 / The Nasdaq Biotechnology Index (IBB) just made a new 52-week high today and most likely an all-time high may not be out of the question either. As most of the market shutters about the trade wars, biotech stocks are more insulated from the biggest concern about tariffs compared to most industries. Biotech companies like GT Biopharma, Inc. (GTBP), Reata Pharmaceuticals (NASDAQ: RETA) and Biogen (NASDAQ: BIIB) have all released news within the last 10 days that has sparked much more interest in the market for these stocks.

  • ACCESSWIRE2 months ago

    Biogen Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 24, 2018 / Biogen Inc. (NASDAQ: BIIB ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 24, 2018 at 8:00 AM Eastern Time. To listen ...

  • ACCESSWIRE2 months ago

    Bill Gates Dedicates $30M into Alzheimer's Treatments

    HENDERSON, NV / ACCESSWIRE / July 23, 2018 / Along with several other philanthropists, Bill Gates recently announced he is putting $30 million into the Diagnostics Accelerator, a "venture philanthropy" fund to develop early diagnostic procedures and bring them to market quickly. One small Alzheimer related biotech firm on our radar is Endonovo Therapeutics, Inc. (ENDV). ENDV could be just one little push from a massive inflection point.

  • GlobeNewswire2 months ago

    AGTC Treats First Patient of Second Cohort in Phase 1/2 Clinical XLRP Study; Earns $10 Million Enrollment Milestone

    Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has enrolled the first patient of the second cohort in the company’s Phase 1/2 clinical trial evaluating the safety and efficacy of an investigational AAV-based gene therapy for the treatment of X-linked retinitis pigmentosa (XLRP). Under the terms of its collaboration with Biogen (BIIB), AGTC will receive a milestone payment of $10 million.

  • GlobeNewswire2 months ago

    Biogen to Host Investor Webcast to Discuss Alzheimer’s Disease Portfolio on July 25, 2018

    Biogen (BIIB) today announced it will host a live webcast providing a Q&A session related to its Alzheimer’s disease investigational therapies on Wednesday, July 25, 2018.  The live webcast will begin at 6:00 p.m. ET/5:00 p.m. CT on July 25, 2018, with Alfred Sandrock, Jr., M.D., Ph.D., executive vice president and chief medical officer at Biogen, and Samantha Budd Haeberlein, Ph.D., vice president, Alzheimer’s disease, dementia and movement disorders, late stage clinical development at Biogen. To access the live webcast, please go to the Investors section of Biogen’s website at www.biogen.com/investors.  Following the live webcast, an archived version of the call will be available on the website.

  • ACCESSWIRE2 months ago

    Wired News – Biogen to Present Data from Alzheimer’s Disease Clinical Development Portfolio at AAIC in Chicago

    LONDON, UK / ACCESSWIRE / July 20, 2018 / If you want access to our free research report on Biogen Inc. (NASDAQ: BIIB), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BIIB as the Company’s latest news hit the wire. On July 18, 2018, the Company declared that it will present data from its Alzheimer’s disease clinical development portfolio at the upcoming Alzheimer’s Association International Conference (AAIC), to be held in Chicago on July 22-26, 2018. Active-Investors.com is currently working on the research report for Orgenesis Inc. (NASDAQ: ORGS), which also belongs to the Healthcare sector as the Company Biogen.

  • GlobeNewswire2 months ago

    Data to be Presented From Biogen's Alzheimer's Disease Clinical Development Portfolio at the 2018 Alzheimer's Association International Conference (AAIC)

    Ongoing Alzheimer`s disease research programs target possible causes of the disease through multiple modalities Data to be presented from Alzheimer`s disease clinical development portfolio including aducanumab, ...

  • GlobeNewswire2 months ago

    Data to be Presented From Biogen’s Alzheimer’s Disease Clinical Development Portfolio at the 2018 Alzheimer’s Association International Conference (AAIC)

    Biogen (BIIB) announced it will present data from its Alzheimer’s disease clinical development portfolio at the upcoming Alzheimer’s Association International Conference (AAIC) in Chicago (July 22-26). Data being presented are part of Biogen’s research programs targeting several of the identified causes of Alzheimer’s disease, focusing on early-stage disease.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Stocks to Watch: Biogen and Amgen

    Shares of Amgen also moved north as Wall Street's celebration of Biogen's news pushed many biotech stocks higher. Biogen Inc. shares were jumping on Friday, closing the day up almost 20% on high volume compared to usual. The company along with Eisai Co. Ltd. of Japan had announced positive results from an Alzheimer's study.

  • Eisai And Biogen Announce Positive Topline Results Of The Final Analysis For BAN2401 At 18 Months
    PR Newswire2 months ago

    Eisai And Biogen Announce Positive Topline Results Of The Final Analysis For BAN2401 At 18 Months

    TOKYO and CAMBRIDGE, Mass., July 5, 2018 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced positive topline results from the Phase II study with BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer's disease. The study achieved statistical significance on key predefined endpoints evaluating efficacy at 18 months on slowing progression in Alzheimer's Disease Composite Score (ADCOMS) and on reduction of amyloid accumulated in the brain as measured using amyloid-PET (positron emission tomography).

  • GlobeNewswire2 months ago

    Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months

    TOKYO and CAMBRIDGE, Mass., July  05, 2018  (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced positive topline results from the Phase II study with BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer`s disease. The study achieved statistical significance on key predefined endpoints evaluating efficacy at 18 months on slowing progression in Alzheimer`s Disease Composite Score (ADCOMS) and on reduction of amyloid accumulated in the brain as measured using amyloid-PET (positron emission tomography).

  • GlobeNewswire2 months ago

    Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months

    Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”) announced positive topline results from the Phase II study with BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer's disease. The study achieved statistical significance on key predefined endpoints evaluating efficacy at 18 months on slowing progression in Alzheimer’s Disease Composite Score (ADCOMS) and on reduction of amyloid accumulated in the brain as measured using amyloid-PET (positron emission tomography).

  • GlobeNewswire3 months ago

    Biogen Exercises Option to Increase Ownership in Samsung Bioepis

    Under the terms of the 2012 joint venture agreement, Biogen will pay Samsung BioLogics approximately $700 million for the option shares, increasing Biogen`s ownership in Samsung Bioepis from approximately 5.4% to approximately 49.9%.  The completion of this share purchase is subject to certain regulatory closing conditions and is expected to close in the second half of 2018.  The exact share purchase price will depend on the timing of the closing and foreign currency exchange rates at that time. "We are very pleased with the progress made to date at Samsung Bioepis and believe exercising this option is an opportunity to create meaningful value for our shareholders," said Michel Vounatsos, chief executive officer at Biogen.

  • GlobeNewswire3 months ago

    Biogen Exercises Option to Increase Ownership in Samsung Bioepis

    Under the terms of the 2012 joint venture agreement, Biogen will pay Samsung BioLogics approximately $700 million for the option shares, increasing Biogen’s ownership in Samsung Bioepis from approximately 5.4% to approximately 49.9%.  The completion of this share purchase is subject to certain regulatory closing conditions and is expected to close in the second half of 2018.  The exact share purchase price will depend on the timing of the closing and foreign currency exchange rates at that time. “We are very pleased with the progress made to date at Samsung Bioepis and believe exercising this option is an opportunity to create meaningful value for our shareholders,” said Michel Vounatsos, chief executive officer at Biogen.

  • ACCESSWIRE3 months ago

    Free Technical Reports on Cerus and Three Additional Biotech Equities

    Losses were broad based as eight out of nine sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: BioDelivery Sciences International Inc. (NASDAQ: BDSI), Biogen Inc. (NASDAQ: BIIB), Biohaven Pharmaceutical Holding Co. Ltd (NYSE: BHVN), and Cerus Corp. (NASDAQ: CERS).